A total of 29,525,760 Common Shares, or 93.02% of the total Common Shares issued and outstanding, were voted by proxy at the meeting. Each director nominee was elected by a show of hands.
Shareholders also voted in favour of the re-appointment of
ABOUT
Formed in 2015, HLS is a specialty pharmaceutical company focused on the acquisition and commercialization of late stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages.
Contact:
Tel: (416) 247-9652
Email: dave.mason@loderockadvisors.com
(C) 2020 Electronic News Publishing, source